Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Protocol PDX-012: A Randomized, Phase 2b, Multi-Center Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-Based Treatment.

Next Previous
X
Search
Trial Profile

Protocol PDX-012: A Randomized, Phase 2b, Multi-Center Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-Based Treatment.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pralatrexate (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Spectrum Pharmaceuticals

    • Most Recent Events

    • 24 Apr 2012 Results published in the Journal of Thoracic Oncology.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database record, EudraCT2007-004673-26).
    • 01 Jul 2011 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top